Literature DB >> 92343

Rapid removal to the liver of intravenously injected lipoprotein lipase.

L Wallinder, G Bengtsson, T Olivecrona.   

Abstract

Lipoprotein lipase was purified from bovine milk and labeled with 125I. After intravenous injection to rats the labeled lipase rapidly disappeared from the blood. The initial half-life was about 1 min and more than 70% of the radioactivity was found in the liver at 10 min. 30 min after the injection about 10% of the injected radioactivity was present in acid-soluble form in blood, indicating that the enzyme had been rapidly degraded. Injection of asialofetuin, ribonuclease B or mannan in amounts known to block the hepatic receptors for glycoproteins with exposed galactose, N-acetylglucosamine or mannose residues did not retard the removal of the lipoprotein lipase. Thus, some other, as yet undefined, receptor is implicated. Lipoprotein lipase is known to bind to heparin and some related polysacchrides. Heparin injected before the enzyme delayed its removal and heparin injected after the enzyme caused an immediate increase in blood radioactivity, signifying return from tissues to blood of labeled enzyme. Lipoprotein lipase is present at the endothelium in several extrahepatic tissues and is rapidly turned over. Its presence in blood in appreciable amounts would cause a derangement of lipid transport. The efficient hepatic removal of the enzyme may thus serve an important physiological purpose in keeping the blood levels of this enzyme low.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 92343     DOI: 10.1016/0005-2760(79)90142-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  Lipoprotein lipase activity in neonatal-rat liver cell types.

Authors:  F Burgaya; J Peinado; S Vilaró; M Llobera; I Ramírez
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

2.  The biliary excretion of enterokinase in rats. Studies in normal, chronic ethanol-maintained and cirrhotic rats.

Authors:  D A Grant; P A Jones; J Hermon-Taylor
Journal:  Biochem J       Date:  1981-08-15       Impact factor: 3.857

3.  Heparin-decasaccharides impair the catabolism of chylomicrons.

Authors:  O Chevreuil; M Hultin; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

4.  Synthesis of lipoprotein lipase in the liver of newborn rats and localization of the enzyme by immunofluorescence.

Authors:  S Vilaró; M Llobera; G Bengtsson-Olivecrona; T Olivecrona
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

5.  Plasma clearance of human extracellular-superoxide dismutase C in rabbits.

Authors:  K Karlsson; S L Marklund
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

6.  Rat liver contains a limited number of binding sites for hepatic lipase.

Authors:  K Schoonderwoerd; A J Verhoeven; H Jansen
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

7.  Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia.

Authors:  K J Williams; K A Petrie; R W Brocia; T L Swenson
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

8.  Forms of lipoprotein lipase in rat tissues: in adipose tissue the proportion of inactive lipase increases on fasting.

Authors:  M Bergö; G Olivecrona; T Olivecrona
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

9.  Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme.

Authors:  G Q Liu; G Bengtsson-Olivecrona; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

10.  Deletion of the basement membrane heparan sulfate proteoglycan type XVIII collagen causes hypertriglyceridemia in mice and humans.

Authors:  Joseph R Bishop; Maria Rita Passos-Bueno; Loren Fong; Kristin I Stanford; Jon C Gonzales; Erika Yeh; Stephen G Young; Andre Bensadoun; Joseph L Witztum; Jeffrey D Esko; Karen S Moulton
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.